Drug Manufacturers – Other
(MDCO) The Medicines Company Earnings Increase
The Medicines Company (MDCO) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company reported a loss of 21 cents per share compared...29Apr2013 | vitalstocks | Comments Off | Continued
(VRTX) Actelion Beats Earnings – Sales Rise
Actelion Ltd. (ALIOF) reported first quarter 2013 earnings of $1.35 per American Depository Receipt (ADR), up 56.1% from the prior-year earnings of 87 cents per ADR. Earnings were well above the Zacks Consensus Estimate...27Apr2013 | vitalstocks | Comments Off | Continued
(WCRX) Warner Chilcott Earns Good News from US Food and Drug Administration
Warner Chilcott plc (WCRX) recently received encouraging news from the US Food and Drug Administration (FDA) when the regulatory agency approved the company’s acne drug Doryx at 200 mg strength (delayed release tablets). The company...23Apr2013 | vitalstocks | Comments Off | Continued
(UTHR) United Therapeutics Corporation to Move Pluristem Therapeutics Drug into Phase I
United Therapeutics Corporation (UTHR) recently gained approval for the commencement of a phase I study in Australia using Pluristem Therapeutics Inc.’s (PSTI)...21Apr2013 | vitalstocks | Comments Off | Continued
(PCYC) Pharmacyclics Earns 4th Milestone
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus chlorambucil in elderly patients...21Apr2013 | vitalstocks | Comments Off | Continued
(ENDP) Actavis Files ANDA for Endo Health Solutions Product
Actavis, Inc. (ACT) recently announced that it is looking to get its generic version of Endo Health Solutions Inc.’s (ENDP) Fortesta (testosterone gel 10mg/0.5g)...6Mar2013 | vitalstocks | Comments Off | Continued
(LCI) UCB In-licenses Parkinson’s Drug
UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies. The Candidate Tozadenant is an orally administered, selective inhibitor...5Mar2013 | Shawn | Comments Off | Continued
(CBST) Cubist Pharmaceuticals Sees Encouraging News From FDA
Recently, Cubist Pharmaceuticals Inc. (CBST) received some encouraging news when the US Food and Drug Administration (FDA) designated its antibiotic candidate CXA-201 (ceftolozane/tazobactam) as a qualified infectious disease product...5Mar2013 | Shawn | Comments Off | Continued
(AGN) Allergan Earnings Miss but Guidance Tops
Allergan, Inc. (AGN) reported fourth quarter 2012 earnings of $1.15 per share, missing the Zacks Consensus Estimate of $1.19 per share. While earnings increased 15.0% from the year-ago quarter, revenues increased 7.6% to $1,508.9...24Feb2013 | Shawn | Comments Off | Continued
(AMRN) Amarin Corporation Aims to Fortify Vascepa Patent
Amarin Corporation plc (AMRN), recently announced that the notice of patent allowance for US application serial number 13/610,217 has been published by the US Patent and Trademark Office (USPTO). The patent application aims to protect...23Jan2013 | Shawn | Comments Off | Continued
(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback
ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with...16Jan2013 | Shawn | Comments Off | Continued
(GERN) Geron’s Update on Stem Cell Assets
Geron Corporation (GERN) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. (BTX) and BioTime’s recently formed subsidiary, BioTime...16Jan2013 | Shawn | Comments Off | Continued
(MDCO) The Medicines Company Sees Positive Results on Cangrelor
The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being developed for the prevention of platelet activation and aggregation that...15Jan2013 | Shawn | Comments Off | Continued
(OREX) Orexigen Therapeutics Provides Update on Obesity Drug Candidate
Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, which had received a complete response letter (CRL) from the US Food and Drug Administration (FDA) in Jan 2011 for Contrave,...15Jan2013 | Shawn | Comments Off | Continued
(UTHR) United Therapeutics Reiterated at Neutral
We recently reiterated a Neutral recommendation on United Therapeutics (UTHR). While the company reported strong third-quarter results, United Therapeutics suffered a major blow in October with the US Food and Drug Administration...2Jan2013 | Shawn | Comments Off | Continued
(FRX) Synergy Pharmaceuticals Shows Pipeline Progress
Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the treatment of patients suffering from constipation-predominant irritable bowel syndrome (IBS-C). Synergy Pharma will be enrolling 350...1Jan2013 | Shawn | Comments Off | Continued
(NVO) Novo Nordisk’s Ryzodeg Approved in Japan
Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted for regulatory approval...1Jan2013 | Shawn | Comments Off | Continued
(MDCO) The Medicines Company Strikes Two Deals
The Medicines Company (MDCO) recently signed two agreements in a bid to boost its top line. While one agreement relates to the in-licensing of a product, the other is an acquisition deal. Both deals will see the company making upfront...23Dec2012 | Shawn | Comments Off | Continued
(ISIS) Isis Pharmaceuticals and AstraZeneca Ink Deal
Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover and develop five new generation antisense...16Dec2012 | Shawn | Comments Off | Continued
(VRTX) Vertex Pharmaceuticals Posts Disappointing Quarter
Vertex Pharmaceuticals Inc. (VRTX) posted break-even (including stock-based compensation expense) results in the third quarter of 2012, well below the year-ago earnings of 56 cents per share. Third quarter results missed the Zacks...24Nov2012 | vitalstocks | Comments Off | Continued
(ARNA) Arena Pharmaceuticals Initiates PAH Study
Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being developed for the treatment of pulmonary arterial hypertension (PAH). Arena Pharma is expecting to enroll 30 healthy...23Oct2012 | vitalstocks | Comments Off | Continued
(ISIS) Isis Pharmaceuticals Owns 18% of Regulus
Isis Pharmaceuticals, Inc. (ISIS) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics Inc.’s (RGLS) common stock at the...14Oct2012 | vitalstocks | Comments Off | Continued
(TEVA) Teva Pharmaceutical Industries Acquires Huntington Candidate
Teva Pharmaceutical Industries Ltd (TEVA) recently announced a deal that will expand the company’s central nervous system (CNS) pipeline. Teva acquired all rights, assets and obligations relating to Huntexil (pridopidine / ACR16)...10Oct2012 | vitalstocks | Comments Off | Continued
(RDY) Generic Launch at Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Merck & Co’s (MRK) Singulair oral granules (montelukast) following the...9Oct2012 | vitalstocks | Comments Off | Continued
(LCI) Lannet’s Generic Fioricet Approved
Lannett Company, Inc. (LCI) recently announced that the US Food and Drug Administration (FDA) granted approval to the company’s abbreviated new drug application (ANDA) for its generic version of Watson Pharmaceuticals Inc.’s...9Oct2012 | vitalstocks | Comments Off | Continued
(RDY) Dr. Reddy’s Laboratories Launches Generic Toprol
Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca’s (AZN) hypertension drug Toprol XL (metoprolol succinate extended...13Sep2012 | vitalstocks | Comments Off | Continued
(PCYC) Pharmacyclics Earns Milestone
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase II study that is being conducted with ibrutinib in patients suffering from relapsed or refractory mantle cell lymphoma (MCL). With the enrollment...28Aug2012 | vitalstocks | Comments Off | Continued
(AGN) Allergan-Molecular Extend Contracts
Allergan Inc. (AGN) and Molecular Partners AG recently announced the expansion of their existing partnership with two separate agreements for the discovery, development and commercialization of their proprietary candidate, DARPin (MP0260). ...27Aug2012 | vitalstocks | Comments Off | Continued
(RDY) Merck KGaA to Acquire Biochrom AG
Merck KGaA (MKGAF) recently announced a definitive agreement to acquire Berlin, Germany-based Biochrom AG. Biochrom AG, which specializes in the production and marketing of cell culture media and buffer solutions, posted sales of...26Aug2012 | vitalstocks | Comments Off | Continued
(MDCO) Medicines Company – Bull of the Day
Medicines Company (MDCO) was upgraded from Neutral to Outperform following a solid earnings report and positive earnings surprise. The beat was positive but we are also excited by the progress in the...24Aug2012 | vitalstocks | Comments Off | Continued